Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort study

Charles S. Cleeland, Musa Mayer, Nancy A. Dreyer, Yeun Mi Yim, Elaine Yu, Zhaohui Su, Yong Mun, Jeff A Sloan, Peter A. Kaufman

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Limited data exist on the association of symptom burden, daily activity impairment, and work productivity (WP) in patients with advanced breast cancer. This cross-sectional analysis evaluated baseline patient-reported outcomes (PROs) in patients with locally recurrent or metastatic breast cancer (MBC) receiving first-line hormonal therapy or chemotherapy and/or targeted therapy in the VIRGO observational study. The primary PRO study endpoint, symptom severity and interference score, was measured using the MD Anderson Symptom Inventory (MDASI). Secondary endpoints included Activity Level Scale (ALS), health-related quality of life (HRQOL), and Work Productivity and Activity Impairment Questionnaire (WPAI:SHP) scores. Overall, 152 patients (chemotherapy cohort, 104; hormonal therapy cohort, 48) answered questionnaires. Fatigue, decreased sexual interest, disturbed sleep, emotional distress, and drowsiness were the most common severe symptoms, and were of moderate-to-severe intensity in 38.8%-52.0% of patients. Mean percent daily activity impairment was 30% for study patients, and WP impairment ranged from 20% to 40% across indices in employed patients (. n, 58). Significant positive correlations existed for MDASI severity and interference scores with activity impairment and WP indices (Pearson correlation coefficients [. R]=0.47-0.82; p<0.0001). ALS and overall HRQOL correlated negatively with these indices (. R=-0.41 to-0.60; p≤0.001). After adjustment for potential confounders, MDASI symptom interference and ALS were significant predictors of activity and WP impairment. Our results indicate patients receiving treatment for MBC are symptomatic with significant daily activity and/or WP impairment. Symptom severity and interference, functional status, and overall HRQOL were moderately correlated with perceived work-related ability.

Original languageEnglish (US)
Pages (from-to)763-769
Number of pages7
JournalBreast
Volume23
Issue number6
DOIs
StatePublished - Dec 1 2014

Fingerprint

Aptitude
Observational Studies
Cohort Studies
Breast Neoplasms
Efficiency
Quality of Life
Equipment and Supplies
Drug Therapy
Sleep Stages
Therapeutics
Health Status
Fatigue
Sleep
Cross-Sectional Studies
Outcome Assessment (Health Care)

Keywords

  • Breast neoplasms
  • Quality of life
  • Symptom assessment
  • Work

ASJC Scopus subject areas

  • Surgery

Cite this

Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer : Results from a substudy of the VIRGO observational cohort study. / Cleeland, Charles S.; Mayer, Musa; Dreyer, Nancy A.; Yim, Yeun Mi; Yu, Elaine; Su, Zhaohui; Mun, Yong; Sloan, Jeff A; Kaufman, Peter A.

In: Breast, Vol. 23, No. 6, 01.12.2014, p. 763-769.

Research output: Contribution to journalArticle

Cleeland, Charles S. ; Mayer, Musa ; Dreyer, Nancy A. ; Yim, Yeun Mi ; Yu, Elaine ; Su, Zhaohui ; Mun, Yong ; Sloan, Jeff A ; Kaufman, Peter A. / Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer : Results from a substudy of the VIRGO observational cohort study. In: Breast. 2014 ; Vol. 23, No. 6. pp. 763-769.
@article{48e06fac86a84a36b452056fe5384c65,
title = "Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort study",
abstract = "Limited data exist on the association of symptom burden, daily activity impairment, and work productivity (WP) in patients with advanced breast cancer. This cross-sectional analysis evaluated baseline patient-reported outcomes (PROs) in patients with locally recurrent or metastatic breast cancer (MBC) receiving first-line hormonal therapy or chemotherapy and/or targeted therapy in the VIRGO observational study. The primary PRO study endpoint, symptom severity and interference score, was measured using the MD Anderson Symptom Inventory (MDASI). Secondary endpoints included Activity Level Scale (ALS), health-related quality of life (HRQOL), and Work Productivity and Activity Impairment Questionnaire (WPAI:SHP) scores. Overall, 152 patients (chemotherapy cohort, 104; hormonal therapy cohort, 48) answered questionnaires. Fatigue, decreased sexual interest, disturbed sleep, emotional distress, and drowsiness were the most common severe symptoms, and were of moderate-to-severe intensity in 38.8{\%}-52.0{\%} of patients. Mean percent daily activity impairment was 30{\%} for study patients, and WP impairment ranged from 20{\%} to 40{\%} across indices in employed patients (. n, 58). Significant positive correlations existed for MDASI severity and interference scores with activity impairment and WP indices (Pearson correlation coefficients [. R]=0.47-0.82; p<0.0001). ALS and overall HRQOL correlated negatively with these indices (. R=-0.41 to-0.60; p≤0.001). After adjustment for potential confounders, MDASI symptom interference and ALS were significant predictors of activity and WP impairment. Our results indicate patients receiving treatment for MBC are symptomatic with significant daily activity and/or WP impairment. Symptom severity and interference, functional status, and overall HRQOL were moderately correlated with perceived work-related ability.",
keywords = "Breast neoplasms, Quality of life, Symptom assessment, Work",
author = "Cleeland, {Charles S.} and Musa Mayer and Dreyer, {Nancy A.} and Yim, {Yeun Mi} and Elaine Yu and Zhaohui Su and Yong Mun and Sloan, {Jeff A} and Kaufman, {Peter A.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.breast.2014.08.004",
language = "English (US)",
volume = "23",
pages = "763--769",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "6",

}

TY - JOUR

T1 - Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer

T2 - Results from a substudy of the VIRGO observational cohort study

AU - Cleeland, Charles S.

AU - Mayer, Musa

AU - Dreyer, Nancy A.

AU - Yim, Yeun Mi

AU - Yu, Elaine

AU - Su, Zhaohui

AU - Mun, Yong

AU - Sloan, Jeff A

AU - Kaufman, Peter A.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Limited data exist on the association of symptom burden, daily activity impairment, and work productivity (WP) in patients with advanced breast cancer. This cross-sectional analysis evaluated baseline patient-reported outcomes (PROs) in patients with locally recurrent or metastatic breast cancer (MBC) receiving first-line hormonal therapy or chemotherapy and/or targeted therapy in the VIRGO observational study. The primary PRO study endpoint, symptom severity and interference score, was measured using the MD Anderson Symptom Inventory (MDASI). Secondary endpoints included Activity Level Scale (ALS), health-related quality of life (HRQOL), and Work Productivity and Activity Impairment Questionnaire (WPAI:SHP) scores. Overall, 152 patients (chemotherapy cohort, 104; hormonal therapy cohort, 48) answered questionnaires. Fatigue, decreased sexual interest, disturbed sleep, emotional distress, and drowsiness were the most common severe symptoms, and were of moderate-to-severe intensity in 38.8%-52.0% of patients. Mean percent daily activity impairment was 30% for study patients, and WP impairment ranged from 20% to 40% across indices in employed patients (. n, 58). Significant positive correlations existed for MDASI severity and interference scores with activity impairment and WP indices (Pearson correlation coefficients [. R]=0.47-0.82; p<0.0001). ALS and overall HRQOL correlated negatively with these indices (. R=-0.41 to-0.60; p≤0.001). After adjustment for potential confounders, MDASI symptom interference and ALS were significant predictors of activity and WP impairment. Our results indicate patients receiving treatment for MBC are symptomatic with significant daily activity and/or WP impairment. Symptom severity and interference, functional status, and overall HRQOL were moderately correlated with perceived work-related ability.

AB - Limited data exist on the association of symptom burden, daily activity impairment, and work productivity (WP) in patients with advanced breast cancer. This cross-sectional analysis evaluated baseline patient-reported outcomes (PROs) in patients with locally recurrent or metastatic breast cancer (MBC) receiving first-line hormonal therapy or chemotherapy and/or targeted therapy in the VIRGO observational study. The primary PRO study endpoint, symptom severity and interference score, was measured using the MD Anderson Symptom Inventory (MDASI). Secondary endpoints included Activity Level Scale (ALS), health-related quality of life (HRQOL), and Work Productivity and Activity Impairment Questionnaire (WPAI:SHP) scores. Overall, 152 patients (chemotherapy cohort, 104; hormonal therapy cohort, 48) answered questionnaires. Fatigue, decreased sexual interest, disturbed sleep, emotional distress, and drowsiness were the most common severe symptoms, and were of moderate-to-severe intensity in 38.8%-52.0% of patients. Mean percent daily activity impairment was 30% for study patients, and WP impairment ranged from 20% to 40% across indices in employed patients (. n, 58). Significant positive correlations existed for MDASI severity and interference scores with activity impairment and WP indices (Pearson correlation coefficients [. R]=0.47-0.82; p<0.0001). ALS and overall HRQOL correlated negatively with these indices (. R=-0.41 to-0.60; p≤0.001). After adjustment for potential confounders, MDASI symptom interference and ALS were significant predictors of activity and WP impairment. Our results indicate patients receiving treatment for MBC are symptomatic with significant daily activity and/or WP impairment. Symptom severity and interference, functional status, and overall HRQOL were moderately correlated with perceived work-related ability.

KW - Breast neoplasms

KW - Quality of life

KW - Symptom assessment

KW - Work

UR - http://www.scopus.com/inward/record.url?scp=84921955473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921955473&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2014.08.004

DO - 10.1016/j.breast.2014.08.004

M3 - Article

C2 - 25193423

AN - SCOPUS:84921955473

VL - 23

SP - 763

EP - 769

JO - Breast

JF - Breast

SN - 0960-9776

IS - 6

ER -